Go to deals
Healthcare

Poolbeg Pharma has completed an Initial Public Offering on AIM

Poolbeg Pharma Plc has raised funds to develop the company.

Poolbeg Pharma is a clinical-stage, infectious disease pharmaceutical company with a capital light clinical model which aims to develop multiple products faster and more cost-effectively than the conventional biotech model, aspiring to become a one-stop shop for Big Pharma seeking mid-stage products to license or acquire. The company was formed from a spin-out of assets from Open Orphan Plc and is headquartered in London, UK.

Oaklins Cavendish’s sister firm finnCap, based in the UK, in its role as IPO advisor, assisted Poolbeg Pharma’s management team and shareholders all the way from the start to the successful completion of the IPO. During this process, the team initiated and advised on many aspects, including, among others, securing commitments from investors, asset spin out deal structuring, EIS eligibility, and the IPO pricing and sizing.

Talk to the deal team

 Peter  Gray

Peter Gray

Partner
London, United Kingdom
Oaklins Cavendish

Related deals

Sopheon has been acquired by Wellspring Worldwide
TMT

Sopheon has been acquired by Wellspring Worldwide

The shareholders of Sophean plc. have sold the company to Wellspring Worldwide.

Learn more
APF Holdings attracts growth funding through a private bond placement from CVI
Agriculture | Food & Beverage

APF Holdings attracts growth funding through a private bond placement from CVI

APF Holdings, which includes one of the largest Baltic egg producers, SIA Alūksnes putnu ferma, has successfully secured US$7.6 million from a private bond placement. CVI acquired the entire volume of the bond issue. The maturity for the bonds is set at four years.

Learn more
Velocys secures $40M of growth capital
Energy

Velocys secures $40M of growth capital

Velocys has completed a fundraising with Carbon Direct Capital, Lightrock, GenZero and Kibo Invest.

Learn more